Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial

Moderate-intensity statin plus ezetimibe versus high-intensity statin alone may provide a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients with recent ischemic stroke. This randomized, open-label, controlled trial assigned patients with recent ischemic stroke

Saved in:
Bibliographic Details
Published in:Journal of stroke 2023-05, Vol.25 (2), p.242-250
Main Authors: Hong, Keun-Sik, Bang, Oh Young, Park, Jong-Ho, Jung, Jin-Man, Lee, Sang-Hun, Song, Tae-Jin, Nam, Hyo Suk, Park, Hee-Kwon, Jung, Keun-Hwa, Heo, Sung Hyuk, Koo, Jaseong, Yu, Kyung-Ho, Park, Kwang-Yeol, Kim, Chi Kyung, Park, Hong-Kyun, Lee, Jiyoon, Lee, Juneyoung, Seo, Woo-Keun
Format: Article
Language:English
Subjects:
ezetimibe
ldl cholesterol
Original
rosuvastatin
stroke
target goal
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Moderate-intensity statin plus ezetimibe versus high-intensity statin alone may provide a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients with recent ischemic stroke. This randomized, open-label, controlled trial assigned patients with recent ischemic stroke
ISSN:2287-6391
2287-6405
DOI:10.5853/jos.2022.02957